XL 228
- CAS NO.:898280-07-4
- Empirical Formula: C22H31N9O
- Molecular Weight: 437.54
- MDL number: MFCD26793867
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-07-02 08:54:57
What is XL 228?
The Uses of XL 228
XL228 is a multi-targeted protein kinase inhibitor in patients with solid tumors or multiple myeloma. It is a COVID19-related research product.
Biological Activity
xl228, a tyrosine kinase inhibitor, is involved in binding to and inhibiting the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (igf1r), src tyrosine kinase, and bcr-abl tyrosine kinase. blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis [1]. xl228 is a multitargeted protein kinase inhibitor targeting igf1r, the aurora kinases, igf-1r, csrc, bcr/abl and src kinases [2].
in vitro
xl228(5-100 nm) reduced cell survival by 10-70% in a dose and time dependent manner and inhibited migration and invasion of two tumors with high propensity to metastasize, fadu and h460. treatment with 50 and 100 nm xl228 abolished the ability of h460, a549 and fadu cells to form colony. at 10 nm, xl228 significantly increased the radiosensitivity of h460, a549 and fadu cells by enhancement factors (ef, at the survival fraction of 0.5) of 1.52, 1.31 and 1.67 respectively. but, in hn-5 cells, sensitization occurred only at 100 nm (ef = 2.27). in hn-5 cells, xl228 (100 nm)incubation induced accumulation of cells at the radiation sensitive g2/m phase of the cell cycle and induced apoptosis in 32% of cells [2].
References
[1] smith d c, britten c, garon e b. a phase i study of xl228, a multitargeted protein kinase inhibitor, in patients with solid tumors or multiple myeloma[j]. j clinoncol, 2010, 28(15s suppl: abstr 3105).
[2] matsumoto f, molkentine d, clary d o, et al. a multi-kinase inhibitor, xl228, enhanced human cancer cell radiosensitivity and suppressed cell invasion and migration[j]. cancer research, 2011, 71(8 supplement): 2487-2487.
[3] smith d c, britten c, clary d o, et al. a phase i study of xl228, a potent igf1r/aurora/src inhibitor, in patients with solid tumors or hematologic malignancies[j]. j clinoncol, 2009, 27(15 suppl): 149s.
Properties of XL 228
storage temp. | Store at -20°C |
solubility | ≥21.9 mg/mL in DMSO; insoluble in H2O; ≥27.6 mg/mL in EtOH with gentle warming and ultrasonic |
form | solid |
color | White to off-white |
Safety information for XL 228
Computed Descriptors for XL 228
New Products
4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
XL-228 >95% CAS 898280-07-4View Details
898280-07-4 -
1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%View Details
99903-60-3 -
1823368-42-8 98%View Details
1823368-42-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%View Details
25408-95-1 -
2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%View Details
1805639-70-6 -
1784294-80-9 98%View Details
1784294-80-9 -
Lithium ClavulanateView Details
61177-44-4